View Carpenter Technology Corporation (CRS) current and estimated P/E ratio data provided by Seeking Alpha.

The researchers found that itacitinib resulted in low CRS grades; 22%, 78%, and 0% of patients had grades 0, 1, and 2 to 5, respectively. (HealthDay News) — For patients with haploidentical ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...

A new chapter was written in Indian Railway history with a successful "rising grade" speed trial in the challenging terrain from Jammu and Kashmir's Katra to Banihal along the USBRL project, a top ...

The researchers found that itacitinib resulted in low CRS grades; 22, 78, and 0 percent of patients had grades 0, 1, and 2 to 5, respectively. No cases of primary graft failure were reported.